- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05831124
A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults
A PHASE 1, RANDOMIZED, DOUBLE-BLIND STUDY OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE WITH AN ADJUVANT ADMINISTERED IN ADULTS 50 THROUGH 64 YEARS OF AGE
The purpose of this clinical trial is to learn about a pneumococcal vaccine with a new ingredient (PF-07872411) intended to enhance the effects of the vaccine. This pneumococcal vaccine with the new ingredient may prevent the diseases caused by pneumococcal bacteria like meningitis, sepsis, ear infections and sinusitis.
Meningitis is an infection in which the tissue around the brain and spine is swollen.
Sepsis is a very serious infection in your blood caused by a germ (a bacteria). Sinusitis is when your sinuses (the air-filled spaces inside your nose and head), are infected.
This study is seeking for healthy participants who:
- are above 50 years of age and less than 64 years of age.
- have not taken any vaccine for pneumococcal diseases before.
- have not taken any vaccines with additional ingredients within 1 year before administration of the study vaccine.
All participants will receive a single study vaccine shot in the upper arm muscle at the study clinic. The study will compare the experiences of people receiving the vaccine with a new ingredient in the vaccine to those without the new ingredient. This will be done by comparing 2 different dose levels of the new ingredient. It will also be compared against people who receive the vaccine without the new ingredient and at different dose levels. This will help the study team establish if the vaccine with a new ingredient is safe and effective.
Participants will take part in this study for about 12 months. During this time participants will have up to 6 clinic visits. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during these visits.
Some participants will need to have blood taken for laboratory tests before they can be judged to be eligible to be included in the study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Pfizer CT.gov Call Center
- Phone Number: 1-800-718-1021
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
Study Locations
-
-
Florida
-
Hialeah, Florida, United States, 33012
- Indago Research & Health Center, Inc
-
Hollywood, Florida, United States, 33024
- Research Centers of America ( Hollywood )
-
-
Maryland
-
Columbia, Maryland, United States, 21045
- Centennial Medical Group
-
Elkridge, Maryland, United States, 21075
- Centennial Medical Group
-
-
Nebraska
-
Omaha, Nebraska, United States, 68134
- Velocity Clinical Research, Omaha
-
-
New York
-
Rochester, New York, United States, 14609
- Rochester Clinical Research, LLC
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Clinical Trials of Texas, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female participants ≥50 and ≤64 years of age at the time of consent.
- Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including those with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease, within 6 months before receipt of study intervention.
- Female participants of childbearing potential or male participants able to father children and who are willing to use acceptable methods of contraception for at least 28 days after the last dose of study intervention; or female participants not of childbearing potential; or male participants not able to father children.
Exclusion Criteria:
- History of a severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component in pneumococcal conjugate vaccines and any other diphtheria toxoid-containing vaccine.
- Serious chronic disorder, including history of metastatic malignancy, severe COPD requiring supplemental oxygen, end-stage renal disease with or without dialysis, cirrhosis of the liver, clinically unstable cardiac disease, or any other disorder, that in the investigator's opinion, would make the participant inappropriate for entry into the study.
- History of microbiologically proven invasive disease caused by S pneumoniae.
- Current febrile illness (body temperature ≥100.4°F [≥38.0°C]) or other acute illness within 48 hours before study intervention administration.
- Pregnant female participants or breastfeeding female participants (known or suspected).
- Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation.
- Receipt of any inactivated or otherwise nonlive vaccine within 14 days or any live vaccine within 28 days before administration of study intervention.
- Receipt of an adjuvanted vaccine containing QS-21 (or similar saponin adjuvant), MPL, or MF59 within 1 year before administration of study intervention
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low dose multivalent pneumococcal conjugate vaccine formulation A
Stage 1 - Participants will be randomized to receive a single injection.
|
Biological
|
Experimental: Low dose multivalent pneumococcal conjugate vaccine formulation B
Stage 2 - Participants will be randomized to receive a single injection.
|
Biological
|
Active Comparator: Low dose of multivalent pneumococcal conjugate vaccine control
Primary control - Stages 1 and 2 - Participants will be randomized to receive a single injection.
|
low dose multivalent pneumococcal conjugate vaccine
Other Names:
|
Active Comparator: Standard dose multivalent pneumococcal conjugate vaccine control
Control - Stages 1 and 2 - Participants will be randomized to receive a single injection.
|
multivalent pneumococcal conjugate vaccine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants reporting local reactions within 7 days after vaccination
Time Frame: 7 days
|
Local reactions (redness, swelling, pain at the injection site) after vaccination.
|
7 days
|
Percentage of participants reporting systemic events within 7 days after vaccination
Time Frame: 7 days
|
Systemic events (fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain, and joint pain) after vaccination.
|
7 days
|
Percentage of participants reporting Adverse Events (AEs) within 1 month after vaccination
Time Frame: 1 month
|
Adverse Events occurring within 1 month after vaccination.
|
1 month
|
Percentage of participants reporting Serious Adverse Events (SAEs) within 6 months after vaccination
Time Frame: 6 months
|
SAEs occurring within 6 months after vaccination.
|
6 months
|
Percentage of participants reporting Serious Adverse Events (SAEs) withing 12 months after vaccination
Time Frame: 12 months
|
SAEs occurring within 12 months after vaccination.
|
12 months
|
Percentage of participants reporting Newly Diagnosed Chronic Medical Conditions (NDCMCs) within 6 months after vaccination
Time Frame: 6 months
|
NDCMCs occurring within 6 months after vaccination.
|
6 months
|
Percentage of participants reporting Newly Diagnosed Chronic Medical Conditions (NDCMCs) withing 12 months after vaccination
Time Frame: 12 months
|
NDCMCs occurring within 12 months after vaccination.
|
12 months
|
Percentage of participants reporting Medically Attended Adverse Events (MAAEs) within 6 months after vaccination
Time Frame: 6 months
|
MAAEs occurring within 6 months after vaccination.
|
6 months
|
Percentage of participants reporting Medically Attended Adverse Events (MAAEs) within 12 months after vaccination
Time Frame: 12 months
|
MAAEs occurring within 12 months after vaccination.
|
12 months
|
Stage 1 and Stage 2 Only - Percentage of participants with abnormal hematology and chemistry laboratory values 2 weeks after vaccination
Time Frame: 2 weeks
|
Abnormal hematology and chemistry laboratory values occurring 2 weeks after vaccination.
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pneumococcal opsonophagocytic activity (OPA) titers
Time Frame: 1 month
|
OPA geometric mean titers (GMTs) 1 month after vaccination
|
1 month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C4941001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumococcal Disease
-
Johns Hopkins Bloomberg School of Public HealthPfizer; National Institutes of Health (NIH); Centers for Disease Control and...CompletedInvasive Pneumococcal Disease | Pneumococcal Nasopharyngeal ColonizationUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerCompletedInvasive Pneumococcal DiseaseIceland
-
Centers for Disease Control and PreventionKaiser PermanenteCompletedPneumococcal Disease PreventionUnited States
-
Walvax Biotechnology Co., Ltd.Enrolling by invitationPneumococcal Disease, InvasiveIndonesia
-
PfizerCompletedInvasive Pneumococcal DiseaseSpain
-
Institut National de la Santé Et de la Recherche...CompletedPneumococcal DiseasesFrance
-
Murdoch Childrens Research InstituteRoyal Children's HospitalCompletedPrimary Immunodeficiency | Invasive Pneumococcal Disease, Protection Against | Invasive Pneumococcal Disease, Recurrent Isolated, 1 | Invasive Pneumococcal Disease, Recurrent Isolated, 2Australia, New Zealand
-
PfizerKaiser PermanenteCompletedInvasive Pneumococcal DiseaseUnited States
-
GlaxoSmithKlineCompletedProphylactic Pneumococcal DiseasesBelgium
-
PfizerCompletedPneumococcal Disease | 13-valent Pneumococcal VaccineUnited States
Clinical Trials on Low dose multivalent pneumococcal conjugate vaccine formulation A
-
PfizerCompletedPneumococcal InfectionsUnited States
-
PfizerRecruitingPneumococcal DiseaseUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedPneumonia | Pneumococcal Infections | Streptococcus Pneumoniae InfectionsBangladesh
-
SanofiCompletedPneumoccocal ImmunisationUnited States
-
PfizerCompletedPneumococcal InfectionsUnited States
-
PfizerTerminatedPneumococcal InfectionsUnited States
-
CanSino Biologics Inc.Henan Center for Disease Control and PreventionCompletedRespiratory Tract Infections | Respiratory Tract Diseases | PneumoniaChina
-
SanofiCompletedPneumococcal Infections | Streptococcus Pneumoniae Infections | Pneumococcal PneumoniaSwitzerland
-
GlaxoSmithKlineCompletedInfections, StreptococcalCzechia
-
Sanofi Pasteur, a Sanofi CompanyCompletedPneumococcal Infections | Streptococcus Pneumoniae Infections | Pneumococcal PneumoniaSwitzerland